Leukapheresis Market

Terumo BCT (US) and Fresenius SE & Co. KGaA (Germany) are the Major Players in the Leukapheresis Market

The global leukaphereis products market is projected to reach USD 91 million by 2026 from USD 61 million in 2021, at a CAGR of 8.4% during the forecast period. The leukopaks market is expected to reach USD 662 million by 2026, at a CAGR of 41.9%. Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. The increasing incidence and prevalence of leukemia and growing demand for leukopaks for research applications are some of the factors driving the growth of these markets. However, the high cost of therapeutic leukapheresis andc cellular therapies, stringent donor recruitment criteria, and long procedural time for leukapheresis are restraining the growth of this market to a certain extent.

The global leukapheresis market is consolidated with the presence few big players in the market. Terumo BCT (US), Fresenius SE & Co. KGaA (Germany), Asahi Kasei Medical Co. Ltd. (Japan), and Haemonetics Corporation (US) are the major players in this market. Some prominent players in the global leukopaks market are Charles River Laboratories (US), AllCells,LLC (US), StemExpress, LLC (US), Precision for Medicine (US), and BioIVT (US). These companies adopted strategies such as acquisitions, partnerships, agreements, collaborations, expansions, and product launches to enhance their presence in the leukapheresis products and leukopaks market.

To know about the assumptions considered for the study download the pdf brochure

Terumo BCT is a leading player in the leukapheresis products market and accounted for the largest share of the market in 2020. The company offers apheresis equipment with the WBC removal protocol. The company focuses on capitalizing on the increased opportunities for adopting new therapies in response to unmet medical needs in the therapeutic apheresis business by prioritizing investments in strategically important emerging countries. In October 2018, the company collaborated with UniCAR Therapy Bio-Medicine Technology Co. (China) to allow the former company to utilize Terumo’s cell expansion devices to automate its manufacturing process for chimeric antigen receptor (CAR) T-cell therapy.

Charles River Laboratories  accounted for the largest share in leukopaks market in 2020. In January 2020, the company acquired HemaCare Corporation, a provider of human-derived cellular products, including leukopaks, which expanded Charles River’s capabilities in the cell therapy market. Similarly, in August 2020, the company acquired Cellero, a provider of cellular products for cell therapy developers and manufacturers.

Related Reports:

Leukapheresis Market by Product (Devices, Filters, Columns, Disposables), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2026

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

Report Code
MD 6538
RI Published ON
4/6/2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Leukapheresis Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved